GWP
ATNM icon

Gen-Wealth Partners’s Actinium Pharmaceuticals ATNM Stock Holding History

Gen-Wealth Partners’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107K Sell
107,111
-20
-0% -$24 0.03% 320
2025
Q4 		$146K Sell
107,131
-2,250
-2% -$3.28K 0.05% 290
2025
Q3 		$175K Buy
+109,381
New +$178K 0.06% 257

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gen-Wealth Partners's ATNM Position: Q1 2026 in Review

Gen-Wealth Partners reduced its Actinium Pharmaceuticals (ATNM) stake by 0.02% in Q1 2026, selling an estimated $24 and leaving 107,111 shares worth $107K. The position accounts for 0.03% of the portfolio, ranked #320.

Gen-Wealth Partners first reported a position in ATNM in Q3 2025 and has held it in 3 quarters since. The position peaked at $175K in Q3 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Gen-Wealth Partners held 107,111 shares of Actinium Pharmaceuticals worth $107K as of Q1 2026.
  • Gen-Wealth Partners sold 20 Actinium Pharmaceuticals shares in Q1 2026, an estimated $24.
  • Actinium Pharmaceuticals made up 0.03% of Gen-Wealth Partners's portfolio in Q1 2026, its #320 holding.
  • Gen-Wealth Partners first reported a position in Actinium Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Gen-Wealth Partners's Actinium Pharmaceuticals position peaked at $175K in Q3 2025.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.